Tudorza Pressair

Chemical Nameaclidinium bromide inhalation powder
Dosage FormPowder (inhalation; 400 mcg)
Drug ClassAnticholinergics
SystemRespiratory
CompanyAstraZeneca
Approval Year2012

Indication

  • For the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
Last updated on 4/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tudorza Pressair (aclidinium bromide inhalation powder) Prescribing Information.2019Circassia Pharmaceuticals Inc., Morrisville, NC